Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II
Abstract
Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5‐yearly doses. In 1465 representative community‐based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self‐reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub‐optimal coverage.
Source: Internal Medicine Journal - Category: Internal Medicine Authors: Timothy M. E. Davis, Jane Kauhanen, Wendy A. Davis Tags: Brief Communication Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Insulin | Internal Medicine | Meningitis Vaccine | Pneomococcal Vaccine | Pneumonia | Study | Vaccines